Context Therapeutics
CNTX
59 hedge funds and large institutions have $206M invested in Context Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
115% more capital invested
Capital invested by funds: $95.9M → $206M (+$110M)
40% more funds holding
Funds holding: 42 → 59 (+17)
15.2% more ownership
Funds ownership: 70.98% → 86.17% (+15%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
51% less call options, than puts
Call options by funds: $53K | Put options by funds: $108K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$16.3M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$12.3M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.5M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$6.26M |
| 5 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.71M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$5.47M |
| 3 |
Blackstone Inc
New York
|
-$3.59M |
| 4 |
Millennium Management
New York
|
-$2.75M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.45M |
CNTX Hedge Fund Activity: Q1 2026 in Review
59 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2026, worth a combined $206M — up 115% from $95.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CNTX positions and 7 closed out — a net gain of 18 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $16.3M. The largest seller was Great Point Partners, cutting an estimated $5.71M.
- 59 institutional investors held Context Therapeutics (CNTX) as of Q1 2026, up from 42 in Q4 2025.
- Funds reported $206M of Context Therapeutics stock for Q1 2026, up 115% quarter-over-quarter.
- 25 funds opened new Context Therapeutics positions in Q1 2026 and 7 closed out, a net change of +18 holders.
- The largest Context Therapeutics buyer in Q1 2026 was Soleus Capital Management, an estimated $16.3M added.
- The largest Context Therapeutics seller in Q1 2026 was Great Point Partners, an estimated $5.71M sold.
Based on aggregated 13F filings for Q1 2026.